Literature DB >> 19368530

Shadows across mu-Star? Constitutively active mu-opioid receptors revisited.

Mark Connor1.   

Abstract

Constitutively active mu-opioid receptors (mu* receptors) are reported to be formed following prolonged agonist treatment of cells or whole animals. mu* receptors signal in the absence of activating ligand and a blockade of mu* activation of G-proteins by naloxone and naltrexone has been suggested to underlie the profound withdrawal syndrome precipitated by these antagonists in vivo. In this issue of the Journal, Divin et al. examined whether treatment of C6 glioma cells with mu-opioid receptor agonists produced constitutively active mu-opioid receptors or other commonly reported adaptations to prolonged agonist treatment. Adenylyl cyclase superactivation was readily apparent following agonist treatment but there was no evidence of the formation of constitutively active mu-opioid receptors. This result challenges the notion that prolonged agonist exposure inevitably produces mu* receptors, and is consistent with many studies of adaptations in neurons produced by chronic agonist treatment. The investigators provide no explanation of their failure to see mu* receptors in C6 cells, but this is perhaps understandable because the molecular nature of mu* receptors remains elusive, and the precise mechanisms that lead to their formation are unknown. Without knowing exactly what mu* receptors are, how they are formed and how they signal, understanding their role in cellular adaptations to prolonged opioid treatment will remain impossible. Studies such as this should refocus attention on establishing the molecular mechanisms that underlie that phenomenon of mu* receptors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19368530      PMCID: PMC2697690          DOI: 10.1111/j.1476-5381.2009.00067.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  13 in total

Review 1.  Efficacy as a vector: the relative prevalence and paucity of inverse agonism.

Authors:  Terry Kenakin
Journal:  Mol Pharmacol       Date:  2004-01       Impact factor: 4.436

2.  Cellular mechanisms of opioid tolerance: studies in single brain neurons.

Authors:  M J Christie; J T Williams; R A North
Journal:  Mol Pharmacol       Date:  1987-11       Impact factor: 4.436

3.  In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice.

Authors:  Kirsten M Raehal; John J Lowery; Castigliano M Bhamidipati; Ryan M Paolino; Jennifer R Blair; Danxin Wang; Wolfgang Sadée; Edward J Bilsky
Journal:  J Pharmacol Exp Ther       Date:  2005-02-16       Impact factor: 4.030

4.  Opioid receptor-coupled G-proteins in rat locus coeruleus membranes: decrease in activity after chronic morphine treatment.

Authors:  D E Selley; E J Nestler; C S Breivogel; S R Childers
Journal:  Brain Res       Date:  1997-01-23       Impact factor: 3.252

Review 5.  Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities.

Authors:  Wolfgang Sadée; Danxin Wang; Edward J Bilsky
Journal:  Life Sci       Date:  2004-12-08       Impact factor: 5.037

6.  Effects of morphine withdrawal on micro-opioid receptor-stimulated guanylyl 5'-[gamma-[35S]thio]-triphosphate autoradiography in rat brain.

Authors:  Christian Kirschke; Jan Schadrack; Walter Zieglgänsberger; Rainer Spanagel
Journal:  Eur J Pharmacol       Date:  2002-06-20       Impact factor: 4.432

7.  Neutral antagonist activity of naltrexone and 6beta-naltrexol in naïve and opioid-dependent C6 cells expressing a mu-opioid receptor.

Authors:  M F Divin; F A Bradbury; F I Carroll; J R Traynor
Journal:  Br J Pharmacol       Date:  2009-02-13       Impact factor: 8.739

8.  Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence.

Authors:  Danxin Wang; Kirsten M Raehal; Emil T Lin; John J Lowery; Brigitte L Kieffer; Edward J Bilsky; Wolfgang Sadée
Journal:  J Pharmacol Exp Ther       Date:  2003-11-04       Impact factor: 4.030

9.  Constitutive mu opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence.

Authors:  Z Wang; E J Bilsky; F Porreca; W Sadée
Journal:  Life Sci       Date:  1994       Impact factor: 5.037

10.  Mu-opioid receptor up-regulation and functional supersensitivity are independent of antagonist efficacy.

Authors:  Sunil Sirohi; Priyank Kumar; Byron C Yoburn
Journal:  J Pharmacol Exp Ther       Date:  2007-08-14       Impact factor: 4.030

View more
  2 in total

1.  GPCR theme editorial.

Authors:  G Milligan; J C McGrath
Journal:  Br J Pharmacol       Date:  2009-09       Impact factor: 8.739

2.  Analgesic tone conferred by constitutively active mu opioid receptors in mice lacking β-arrestin 2.

Authors:  Hoa Lam; Matthew Maga; Amynah Pradhan; Christopher J Evans; Nigel T Maidment; Tim G Hales; Wendy Walwyn
Journal:  Mol Pain       Date:  2011-04-12       Impact factor: 3.395

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.